Atherosclerosis Drugs Market
Atherosclerosis Drugs Market Analysis by Anti-platelet Medications, Cholesterol-lowering Medications, Beta Blockers, ACE Inhibitors, Calcium Channel Blockers, and Diuretics from 2023 to 2033
Analysis of Atherosclerosis Drugs Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Atherosclerosis Drugs Market Outlook (2023 to 2033)
The global atherosclerosis drugs market is currently valued at US$ 49.9 billion and is projected to exhibit expansion at 2.3% CAGR over the next ten years to reach a value of US$ 62.8 billion by the end of 2033.
Urbanization has led to some major lifestyle changes across the world which have resulted in a high incidence of health complications such as high blood pressure, diabetes, cardiovascular diseases, and obesity. The aforementioned health issues primarily drive demand for atherosclerosis drugs and are anticipated to witness a slow hike in demand over the next ten years.
Increasing aging population, rising number of cases of cardiovascular disorders, growing incidence of obesity, poor dietary habits, adoption of sedentary lifestyles, and rising investments in healthcare R&D are other prospects that could potentially uplift sales of atherosclerosis drugs in the future.
Growing awareness regarding the risks of high cholesterol and the increasing availability of novel atherosclerosis disorder therapeutics are slated to open up new opportunities for atherosclerosis drug providers across the forecast period.
- As per statistics listed on the World Health Organization (WHO) website, around 1 billion people are suffering from obesity and the organization estimates that around 167 million people will be less healthy due to their obesity by the end of 2025.
High alcohol and tobacco consumption are also expected to have a positive impact on demand for atherosclerosis drugs going forward. Government initiatives to promote awareness regarding the ill effects of obesity and the increasing availability of novel cholesterol medications and cardiomyopathy drugs are expected to create lucrative opportunities for atherosclerosis drug suppliers on a global level.
Asia Pacific is anticipated to emerge as a highly opportunistic market and is expected to lead global demand for atherosclerosis drugs by the end of the forecast period. India, China, and Japan are estimated to be the prime markets in this region where atherosclerosis drug sales are expected to be driven by the increasing geriatric population and rising investments in healthcare infrastructure development. The Asia Pacific regional market is estimated to account for around 25% of the global market share by the end of 2033.
On the flip side, the limited efficacy of certain atherosclerosis drugs and therapeutics and the absence of a definitive therapy to treat atherosclerosis disorders are projected to influentially restrict global market evolution in the long run. Additionally, the high costs associated with atherosclerosis disorder treatment and the lack of skilled professionals are also expected to foil atherosclerosis drug consumption across the forecast period till 2033.
Report Attributes |
Details |
|
Atherosclerosis Drugs Market Size (2023) |
US$ 49.9 Billion |
|
Projected Market Value (2033F) |
US$ 62.8 Billion |
|
Global Market Growth Rate (2023 to 2033) |
2.3% CAGR |
|
Market Share of Hospital Pharmacies (2033) |
~48% |
|
North America Market Share (2022) |
~42% |
|
Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
How Can Start-ups Make a Mark in the Atherosclerosis Drugs Marketplace?
“Innovation & Development of Novel Therapeutics: Prime Focus of New Companies”
New atherosclerosis drug companies are focusing on advancing their R&D to create novel therapeutics that help them compete with established players in the global marketplace. To achieve this, aspiring atherosclerosis drug suppliers are appointing experienced professionals in their establishments that can further advance their business scope.
- In December 2022, Cyclarity Therapeutics, a biotechnology start-up founded in 2019 announced that it had appointed Dr. Noah Rosenberg as the head of clinical affairs. Rosenberg brought more than 20 years of experience from pharma giants such as Pfizer and Sanofi. He was expected to overlook the development of novel treatments for atherosclerosis.
- AFFiRiS, a clinical-stage biopharmaceutical organization based in Austria is focusing on developing antigen-specific immunotherapies for the treatment and prevention of chronic illnesses such as atherosclerosis, neurodegenerative diseases, etc.
- HealthCheck Diagnostics, a start-up based in the United States is trying to reduce the mortality rate in cardiovascular disorders and atherosclerosis affected-patients through its novel biomarker testing technology in a non-invasive procedure.
- International Cardio Corporation, a company based in the United States develops high-intensity-focused ultrasound solutions to treat atherosclerosis in a non-invasive manner that is safer and more efficient for patients.
This updated atherosclerosis drugs market research report by Fact.MR, a market research and competitive intelligence provider, proffers an all-inclusive assessment of how new developments by start-ups are transforming product standards and pricing trends on a global level.
Country-wise Insights
Why are Atherosclerosis Drug Sales Increasing in Japan?
“High Senescent Population Driving Market Evolution”
The world is witnessing a substantial increase in the aging population and this trend has been a prominent factor in Japan for quite a while now, which is expected to drive shipments of atherosclerosis drugs over the coming years. Older people are more at risk of contracting cardiovascular disorders and this is anticipated to bolster atherosclerosis drug sales in the country through 2033.
Increasing investments in the healthcare industry, the rising frequency of the launch of novel generic drugs, and growing awareness about atherosclerosis disorders are other aspects that could supplement market development going forward. Increasing medical research activity in the country will also be pivotal in determining market growth over the next ten years.
- A study published in the European Heart Journal, by researchers from Osaka University in Japan revealed that routine dietary consumption of tricaprin results in regression of coronary artery plaque and resolution of symptoms of triglyceride deposit cardiomyovasculopathy in patients.
Are European Countries Investment-worthy Markets for Atherosclerosis Drug Suppliers?
“Growing Availability of Novel Atherosclerosis Drugs Creating Remunerative Opportunities”
Focus on health has increased exponentially in European countries in recent years owing to the advent of several chronic diseases and heightened awareness among the general population about the same. Increasing investments in healthcare research and supportive government initiatives to promote the adoption of innovative atherosclerosis therapeutics are expected to primarily boost market development in countries such as Germany, France, Italy, and the United Kingdom throughout the forecast period.
Expanding senescent population, rising healthcare expenditure, growing awareness regarding atherosclerosis, and the growing availability of novel atherosclerosis drugs are other prospects that could potentially uplift market growth in European countries. The increasing ubiquity of cardiovascular disorders and increasing disposable income are also forecasted to stimulate atherosclerosis drug demand in the future.
Which Country is Asserting its Dominance in North America?
“United States to Hold Substantial Revenue Share”
The United States is anticipated to account for high atherosclerosis drug shipments throughout the forecast period owing to the growing prevalence of cardiovascular disorders and high incidence of obesity. Poor eating habits, the adoption of sedentary lifestyles, the increasing geriatric population, and the growing availability of drugs to treat atherosclerosis are other prospects that are anticipated to bolster market development in the country throughout the forecast period.
- As per the statistics listed on the Centers for Disease Control and Prevention (CDC) website, one person dies from cardiovascular disease every 34 seconds in the United States and around 805,000 people suffer from a heart attack every year.
Supportive initiatives to promote medical research and the launch of favorable reimbursement and insurance policies are other factors that could uplift atherosclerosis drug sales in the future in the United States. Growing awareness and increasing availability of novel therapeutics to treat atherosclerosis drugs are slated to open up new roads of opportunity for atherosclerosis drug manufacturers in the country going forward.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Category-wise Insights
Which Class of Drugs is Most Sought-after?
“Cholesterol-lowering Medication Sales to Soar Over Decade”
Based on drug class, the atherosclerosis drugs market is segmented into anti-platelet medications, cholesterol-lowering medications, fibric acid & omega-3 fatty acid derivatives, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, diuretics, and others.
High cholesterol levels in an individual lead to obesity and an increased risk of cardiovascular disorders, which leads to high demand for cholesterol-lowering medications to combat the aforementioned ailments. Adoption of sedentary lifestyles, limited physical activity, and growing intake of sugars and calorie-dense foods are factors that lead to high cholesterol levels among individuals across the world.
The development and launch of novel cholesterol-lowering drugs are also expected to bolster growth in this segment throughout the forecast period. Fibrates and statins are some popular cholesterol-lowering medications that are currently widely used for the treatment of atherosclerosis disorders.
Competitive Landscape
Prime atherosclerosis drug suppliers are focusing on launching generic drugs to maximize their sales potential and meet increasing demand in the Asia Pacific region.
- In August 2022, Cadila Pharmaceuticals, an Indian pharmaceutical company announced the launch of generic versions of sitagliptin, which is a drug class of DPP-4 inhibitors used for the treatment of hyperglycaemia that is known to lead to complications such as heart attacks, stroke, and atherosclerosis. The generic versions were launched under the brand names Sitenali and Jankey for type 2 diabetes in India.
Leading atherosclerosis drug manufacturers are focusing on obtaining approvals from regulatory authorities for their products to fast-track their launches.
- Merck & Co. is focusing on obtaining approval for its drugs that are in the development pipeline to attain its revenue goal of US$ 10 billion in the mid-2030s. The company’s atherosclerosis drug MK-0616 is in its phase 2B study that has an estimated completion timeline of February 2023. The drug is an oral treatment expected to lower cholesterol levels in an individual.
Key Segments of Atherosclerosis Drugs Industry Research
-
By Drug Class :
- Anti-platelet Medications
- Cholesterol-lowering Medications
- Fibric Acid and Omega-3 Fatty Acid Derivatives
- Beta Blockers
- Angiotensin-converting Enzyme (ACE) Inhibitors
- Calcium Channel Blockers
- Diuretics
- Others
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
By Region :
- North America
- Latin America
- Europe
- APAC
- MEA
Table of Content
1. Preface 1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary : Global Market 4. Market Overview 4.1. Introduction 4.1.1. Drug Type Definition 4.1.2. Industry Evolution / Developments 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.1.1. Increase in Prevalence of Atherosclerosis & Cardiovascular Diseases 4.3.1.2. Development of New Treatments 4.3.1.3. Rising Awareness about Cardiovascular Diseases 4.3.2. Restraints 4.3.2.1. Availability of Generic Products 4.3.2.2. Low Diagnostic Rate 4.3.3. Opportunities 4.4. Global Market Analysis and Forecast, 2023–2033 5. Market Outlook 5.1. Clinical Trial Pipeline Analysis 5.2. Disease Prevalence & Incidence Rate globally with key countries 5.3. Brand Analysis 6. Global Market Analysis and Forecast, By Drug Class 6.1. Introduction & Definition 6.1.1. Key Findings / Developments 6.2. Global Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033 6.2.1. Anti-platelet Medications 6.2.2. Cholesterol Lowering Medications 6.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives 6.2.4. Beta Blockers 6.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors 6.2.6. Calcium Channel Blockers 6.2.7. Diuretics 6.2.8. Others 6.3. Global Market Attractiveness, by Drug Class 7. Global Market Analysis and Forecast, By Distribution Channel 7.1. Introduction & Definition 7.1.1. Key Findings / Developments 7.2. Global Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033 7.2.1. Retail Pharmacies 7.2.2. Hospital Pharmacies 7.2.3. Online Pharmacies 7.3. Global Market Attractiveness, by Distribution Channel 8. Global Market Analysis and Forecast, By Region 8.1. Key Findings 8.2. Global Market Revenue (US$ Mn) Forecast, by Region 8.2.1. North America 8.2.2. Europe 8.2.3. Asia Pacific 8.2.4. Latin America 8.2.5. Middle East & Africa 8.3. Global Market Attractiveness, by region 9. North America Market Analysis and Forecast 9.1. Introduction 9.1.1. Key Findings 9.2. North America Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033 9.2.1. Anti-platelet Medications 9.2.2. Cholesterol Lowering Medications 9.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives 9.2.4. Beta Blockers 9.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors 9.2.6. Calcium Channel Blockers 9.2.7. Diuretics 9.2.8. Others 9.3. North America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033 9.3.1. Retail Pharmacies 9.3.2. Hospital Pharmacies 9.3.3. Online Pharmacies 9.4. North America Market Revenue (US$ Mn) Forecast, by Country, 2023–2033 9.4.1. U.S. 9.4.2. Canada 9.5. North America Market Attractiveness 9.5.1. By Drug Type 9.5.2. By Distribution Channel 9.5.3. By Country 10. Europe Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. Europe Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033 10.2.1. Anti-platelet Medications 10.2.2. Cholesterol Lowering Medications 10.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives 10.2.4. Beta Blockers 10.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors 10.2.6. Calcium Channel Blockers 10.2.7. Diuretics 10.2.8. Others 10.3. Europe Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033 10.3.1. Retail Pharmacies 10.3.2. Hospital Pharmacies 10.3.3. Online Pharmacies 10.4. Europe Market Revenue (US$ Mn) Forecast, by Country Sub/region, 2023–2033 10.4.1. Germany 10.4.2. U.K. 10.4.3. France 10.4.4. Spain 10.4.5. Italy 10.4.6. Rest of Europe 10.5. Europe Market Attractiveness 10.5.1. By Drug Type 10.5.2. By Distribution Channel 10.5.3. By Country/Sub-region 11. Asia Pacific Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Asia Pacific Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033 11.2.1. Anti-platelet Medications 11.2.2. Cholesterol lowering medications 11.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives 11.2.4. Beta blockers 11.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors 11.2.6. Calcium Channel Blockers 11.2.7. Diuretics 11.2.8. Others 11.3. Asia Pacific Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033 11.3.1. Retail Pharmacies 11.3.2. Hospital Pharmacies 11.3.3. Online Pharmacies 11.4. Asia Pacific Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033 11.4.1. China 11.4.2. Japan 11.4.3. India 11.4.4. Australia & New Zealand 11.4.5. Rest of Asia Pacific 11.5. Asia Pacific Market Attractiveness 11.5.1. By Drug Type 11.5.2. By Distribution Channel 11.5.3. By Country/Sub-region 12. Latin America Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Latin America Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033 12.2.1. Anti-platelet Medications 12.2.2. Cholesterol Lowering Medications 12.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives 12.2.4. Beta blockers 12.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors 12.2.6. Calcium Channel Blockers 12.2.7. Diuretics 12.2.8. Others 12.3. Latin America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033 12.3.1. Retail Pharmacies 12.3.2. Hospital Pharmacies 12.3.3. Online Pharmacies 12.4. Latin America Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033 12.4.1. Brazil 12.4.2. Mexico 12.4.3. Rest of Latin America 12.5. Latin America Market Attractiveness 12.5.1. By Drug Type 12.5.2. By Distribution Channel 12.5.3. By Country/Sub-region 13. Middle East & Africa Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Middle East & Africa Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033 13.2.1. Anti-platelet medications 13.2.2. Cholesterol Lowering Medications 13.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives 13.2.4. Beta blockers 13.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors 13.2.6. Calcium Channel Blockers 13.2.7. Diuretics 13.2.8. Others 13.3. Middle East & Africa Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033 13.3.1. Retail Pharmacies 13.3.2. Hospital Pharmacies 13.3.3. Online Pharmacies 13.4. Middle East & Africa Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033 13.4.1. GCC 13.4.2. South Africa 13.4.3. Rest of Middle East & Africa 13.5. Middle East & Africa Market Attractiveness 13.5.1. By Drug Type 13.5.2. By Distribution Channel 13.5.3. By Country/Sub-region 14. Competition Landscape 14.1. Market Player – Competition Matrix (By Tier and Size of companies) 14.2. Key Company’s Market Ranking Analysis 14.3. Company Profiles 14.3.1. GlaxoSmithKline Plc 14.3.1.1. Company Overview 14.3.1.2. Company Financials 14.3.1.3. Growth Strategies 14.3.1.4. SWOT Analysis 14.3.2. Sanofi 14.3.2.1. Company Overview 14.3.2.2. Company Financials 14.3.2.3. Growth Strategies 14.3.2.4. SWOT Analysis 14.3.3. Hoffmann-La Roche Ltd 14.3.3.1. Company Overview 14.3.3.2. Company Financials 14.3.3.3. Growth Strategies 14.3.3.4. SWOT Analysis 14.3.4. Bayer AG 14.3.4.1. Company Overview 14.3.4.2. Company Financials 14.3.4.3. Growth Strategies 14.3.4.4. SWOT Analysis 14.3.5. Novartis AG 14.3.5.1. Company Overview 14.3.5.2. Company Financials 14.3.5.3. Growth Strategies 14.3.5.4. SWOT Analysis 14.3.6. Merck & Co., Inc. (Merck Sharp & Dohme Corp) 14.3.6.1. Company Overview 14.3.6.2. Company Financials 14.3.6.3. Growth Strategies 14.3.6.4. SWOT Analysis 14.3.7. Janssen Pharmaceuticals, Inc. (Johnson & Johnson) 14.3.7.1. Company Overview 14.3.7.2. Company Financials 14.3.7.3. Growth Strategies 14.3.7.4. SWOT Analysis 14.3.8. Mylan N.V. 14.3.8.1. Company Overview 14.3.8.2. Company Financials 14.3.8.3. Growth Strategies 14.3.8.4. SWOT Analysis 14.3.9. Amgen Inc. 14.3.9.1. Company Overview 14.3.9.2. Company Financials 14.3.9.3. Growth Strategies 14.3.9.4. SWOT Analysis 14.3.10. Pfizer, Inc. 14.3.10.1. Company Overview 14.3.10.2. Company Financials 14.3.10.3. Growth Strategies 14.3.10.4. SWOT Analysis
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Atherosclerosis Pipeline Analysis
Table 02: Atherosclerosis Pipeline Analysis
Table 03: Global Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033
Table 04: Global Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 05: Global Market Revenue (US$ Mn) Forecast, by Region, 2023–2033
Table 06: North America Market Revenue (US$ Mn) Forecast, by Drug Class 2023–2033
Table 07: North America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 08: North America Market Revenue (US$ Mn) Forecast, by Country, 2023–2033
Table 09: Europe Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033
Table 10: Europe Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 11: Europe Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 12: Asia Pacific Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033
Table 13: Asia Pacific Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 14: Asia Pacific Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 15: Latin America Market Revenue (US$ Mn) Forecast, by Drug Class 2023–2033
Table 16: Latin America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 17: Latin America Market Revenue (US$ Mn) Forecast, by Country / Sub-region, 2023–2033
Table 18: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033
Table 19: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 20: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Revenue (US$ Mn) and Distribution (%), by Region, 2023 and 2033
Figure 02: Global Market Revenue (US$ Mn), by Drug Class, 2023
Figure 03: Global Market Revenue Share Analysis, by Drug Class, 2023
Figure 04: Market Overview
Figure 05: Global Market Revenue Share, by Drug Class, 2023
Figure 06: Global Market Revenue Share, by Distribution Channel, 2023
Figure 07: Global Market Revenue Share, by Region, 2023
Figure 08: Global Market Revenue (US$ Mn) Forecast, 2023–2033
Figure 09: Global Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 10: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anti-platelet Medications, 2023–2033
Figure 11: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cholesterol Lowering Medications, 2023–2033
Figure 12: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Fibric Acid and Omega-3 Fatty Acid Derivatives, 2023–2033
Figure 13: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Beta Blockers, 2023–2033
Figure 14: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Angiotensin-converting Enzyme (ACE) Inhibitors, 2023–2033
Figure 15: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Calcium Channel Blockers, 2023–2033
Figure 16: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Diuretics, 2023–2033
Figure 17: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2023–2033
Figure 18: Global Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 19: Global Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 20: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth(%) Projection, by Retail Pharmacies, 2023–2033
Figure 21: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2023–2033
Figure 22: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2023–2033
Figure 23: Global Market Attractiveness Analysis, by Distribution Channel, 2023–2033
Figure 24: Global Market Revenue Share Analysis, by Region, 2023 and 2033
Figure 25: Global Market Attractiveness Analysis, by Region, 2023–2033
Figure 26: North America Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033
Figure 27: North America Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 28: North America Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 29: North America Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 30: North America Market Attractiveness Analysis, by Distribution Channel, 2023 -2033
Figure 31: North America Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 32: North America Market Attractiveness Analysis, by Country/Sub-region, 2023–2033
Figure 33: Europe Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033
Figure 34: Europe Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 35: Europe Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 36: Europe Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 37: Europe Market Attractiveness Analysis, by Distribution Channel, 2023–2033
Figure 38: Europe Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 39: Europe Market Attractiveness Analysis, by Country/Sub-region, 2023–2033
Figure 40: Asia Pacific Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033
Figure 41: Asia Pacific Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 42: Asia Pacific Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 43: Asia Pacific Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 44: Asia Pacific Market Attractiveness Analysis, by Distribution Channel, 2023 -2033
Figure 45: Asia Pacific Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 46: Asia Pacific Market Attractiveness Analysis, by Country/Sub-region, 2023–2033
Figure 47: Latin America Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033
Figure 48: Latin America Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 49: Latin America Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 50: Latin America Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 51: Latin America Market Attractiveness Analysis, by Distribution Channel, 2023 -2033
Figure 52: Latin America Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 53: Latin America Market Attractiveness Analysis, by Country/Sub-region, 2023–2033
Figure 54: Middle East & Africa Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033
Figure 55: Middle East & Africa Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 56: Middle East & Africa Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 57: Middle East & Africa Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 58: Middle East & Africa Market Attractiveness Analysis, by Distribution Channel, 2023 -2033
Figure 59: Middle East & Africa Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 60: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2023–2033
Figure 61: Market Position Analysis, 2023, by Tier and Size of the Company
Figure 62: GlaxoSmithKline plc (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 63: GlaxoSmithKline plc Breakdown of Net Sales (%), by Region/Country, 2023
Figure 64: GlaxoSmithKline plc Revenue Breakdown of Net Sales (%), by Business segment, 2023
Figure 65: GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 66: Sanofi (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 65: GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 68: Sanofi Revenue Breakdown of Net Sales (%), by Pharmaceutical Business segment, 2023
Figure 69: Sanofi R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2023–2023
Figure 70: F. Hoffmann-La Roche Ltd Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 71: F. Hoffmann-La Roche Ltd Breakdown of Net Sales (%), by Region, 2023
Figure 72: F. Hoffmann-La Roche Ltd Breakdown of Net Sales (%), by Pharmaceutical Division, 2023
Figure 73: F. Hoffmann-La Roche Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 74: Bayer AG, Pharmaceutical Revenue (US$ Mn) and Y-o-Y Growth (%), 2023–2023
Figure 75: Bayer AG Breakdown of Net Sales (%), by Region, 2023
Figure 76: Bayer AG Revenue Breakdown of Net Sales (%), by Business segment, 2023
Figure 77: Bayer AG, pharmaceutical segment R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 78: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 79: Novartis AG Breakdown of Net Sales (%) of Innovative Medicines Business Segment, by Region/Country, 2023
Figure 80: Novartis AG Revenue Breakdown of Net Sales (%), by Innovative Medicines Segment, 2023
Figure 81: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 82: Merck & Co., Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 83: Merck & Co., Inc. Breakdown of Net Sales (%), by Region/Country, 2023
Figure 84: Merck & Co., Inc. Revenue Breakdown of Net Sales (%), by Segment, 2023
Figure 85: Merck & Co., Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 86: Johnson & Johnson Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2023–2023
Figure 87: Johnson & Johnson Breakdown of Net Sales (%), of Pharmaceutical Segment by Region/Country, 2023
Figure 88: Johnson & Johnson Revenue Breakdown of Net Sales (%), by Pharmaceutical Segment, 2023
Figure 89: Johnson & Johnson, Pharmaceutical Segment R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2023–2023
Figure 90: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 91: Mylan N.V. R&D Expenses (US$ Mn), 2023–2023
Figure 92: Mylan N.V. Breakdown of Net Sales, by Region, 2023
Figure 93: Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 94: Amgen, Inc. Breakdown of Net Sales (%), by Region/Country, 2023
Figure 95: Amgen Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), by Segment 2014–2023
Figure 96: Pfizer, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 97: Pfizer, Inc. Breakdown of Net Sales, by Geography, 2023
Figure 98: Pfizer, Inc. Breakdown of Net Sales, by Business Segment (%), 2023
Figure 99: Pfizer, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the current size of the atherosclerosis drugs market?
The global atherosclerosis drugs market accounts for a US$ 49.9 billion valuation in 2023.
How big will the market for atherosclerosis drugs be by 2033?
Shipments of atherosclerosis drugs are forecasted to reach a value of US$ 62.8 billion by 2033-end.
At what rate will atherosclerosis drug demand evolve over the next ten years?
From 2023 to 2033, the demand for atherosclerosis drugs is set to rise at 2.3% CAGR.
Which regional market leads global atherosclerosis drug sales?
Demand for atherosclerosis drugs is anticipated to be significant in North America through 2033.
Who are the prime atherosclerosis drug manufacturers?
Key companies in this market are Sanofi, Hoffmann La-Roche Ltd., Bayer AG, Pfizer Inc., Novartis AG, and GlaxoSmithKline Plc.
Atherosclerosis Drugs Market